Response to ‘Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest’

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

    loading  Loading Related Articles